AI workshop for pharma cold chain and GDP.

An AI workshop for pharma cold chain and GDP is a half-day or full-day session that takes a pharma organisation through the practical, legal and operational side of AI in temperature-sensitive medicines distribution. We deliberately work with examples from your own domain: excursions on a 2–8°C route over the Brenner Pass, batch recall impact across a European pharmacy network, serialisation verifiers in wholesaler software, clinical trial materials moving through depot-to-site flows, and stock forecasting for the flu and RSV peak season, rather than generic corporate use cases.

The Netherlands is a natural hub for pharma distribution: Schiphol cargo as a cold-chain hub for clinical research and vaccination programmes, and major 3PL pharma players such as Movianto, DSV Pharma, Kuehne+Nagel KN PharmaChain and CEVA Healthcare, which serve Europe from the Netherlands. Mistakes carry real weight here: an excursion that runs too long means a batch blockade, an incorrect serialisation update means a failed pharmacy verification, and an AI system that influences a release decision falls within Annex 11 and possibly under the high-risk category of the AI Act. We design every workshop around your reality, not around a TMS or WMS vendor's roadmap, and we are also honest about where AI is not the answer.

The second distinguishing point: we come from software development, not management consultancy. We build custom software for healthcare and pharma ourselves, understand the sensitivities of NEN 7510-compliant development, and know how a validated quality system responds to a new AI layer. Which modules we cover depends on the audience: QA and QP lean on governance, validation and GDP-RA; operations and customer service on hands-on work and exception handling; management and IT architecture on costs and TMS/WMS/EBR integration.

What we don't do: pretend that AI makes your QP's release decision redundant. A Qualified Person remains personally responsible for batch release in the European supply chain. What AI can do is give that same QP a richer picture of a possible excursion, prior deviation history or a trend on a specific route, and that is precisely where we focus the session.

During the workshop we work through use cases that will be familiar to pharma organisations: concrete situations to put the legal, technical, validation and operational analysis to the test. Participants discover for themselves where the line falls between a useful assistant and a high-risk system that could affect a batch hold or patient exposure.

A first classic is cold-chain anomaly detection. A pharma 3PL continuously receives IoT feeds from reefer containers, lorries, depot locations and distribution fridges. An AI model can spot patterns ahead of an excursion (a combination of outside temperature, vehicle load, route segment, door openings and gateway latency) that individual threshold rules miss. The value does not lie in replacing the alarm system; the validated data logger remains in place. The value lies in a second signal layer that lets your QA and operations teams act sooner, and in a retrospective tool that speeds up root-cause analysis after an excursion. For the broader supply-chain context, see our transport companion page.

A second is route planning for EU pharma corridors. The major flows (Schiphol to Frankfurt, Rotterdam to Basel, Eindhoven to Mainz, Belgian border corridors) have recurring bottlenecks: border handling with third countries since Brexit, terminal dwell times, weather-sensitive mountain passes, and customs handover. AI models that combine historical ETAs, weather data and earlier excursion logs can suggest routes with a statistically lower temperature risk, as a supporting signal alongside QA's validated shipping-lane choice.

A third is batch recall impact analysis. In a recall, the key question is where a given batch ended up within the distribution timeframe. AI can help aggregate serialisation events (verifier scans, release events, return flows) quickly into an operational picture: which pharmacies, which wholesale depots and which patient populations were affected. We cover which architecture makes that analysis possible and which privacy boundaries apply.

A fourth is inventory forecasting with serialisation and shelf life. Unlike in non-pharma settings, this is not only about FIFO but about FEFO (First Expired, First Out), combined with batch status (released, blocked, quarantined), MAH instructions and, for clinical trials, sponsor protocols. AI forecasts must handle these additional dimensions, otherwise they steer by a reality that does not exist.

A fifth is disruption forecasting for port and border issues. Strikes, terminal outages, sanctions changes and extreme weather disrupt pharma flows especially hard, because rerouting without a validated route is not an option. AI can combine signals from news, terminal publications, AIS data and historical disruptions into an early warning, provided the signal is not mistaken for an operational instruction.

A sixth is audit trail completion and deviation assistance. A Annex 11 or GDP audit requires traceability of changes, deviations and CAPA steps, often scattered across eQMS, email and spreadsheets. AI can help draft narratives that QA then reviews and validates. We cover where that support is responsible and where it becomes risky, namely where AI could paper over a gap in the audit trail.

These cases serve as material for analysis. We walk through each case against AI Act classification, GDP and Annex 11 positioning, data quality and practical feasibility in your stack. At the end, your team will have a shared view of what is sensible to investigate first, and what is not (yet).

There is no separate "AI law" for pharmaceutical distribution, but applying general and sector-specific regulation to AI is no mere formality. Any serious application brings several frameworks to the table at once.

The AI Act classifies AI systems by risk level. Crucial for pharma: Article 4 (AI literacy for everyone who works with AI, not just IT); high-risk classification for systems that influence batch release, clinical trial allocation or patient impact assessments; and the overlap with the MDR/IVDR for medical devices and in-vitro diagnostics. GDP-EU 2013/C 343/01 is the primary framework for good distribution practice: responsible person duties, quality system, validated temperature logging, deviation management and traceability. Annex 11 (EudraLex Volume 4) governs computerised systems: validation, audit trail, electronic signatures and data integrity (ALCOA+). For US MAH flows, 21 CFR Part 11 also applies.

The EU FMD (Regulation 2011/62/EU and 2016/161) requires serialisation and verification at pharmacy level via a national hub system; wholesale and parallel import carry specific verification obligations. AI models operating on these flows must handle purpose limitation, retention and interaction with the NMVS/EU hub correctly. In addition, the GDPR applies as soon as patient or clinical trial participant data is involved, often through patient support, home delivery or post-marketing surveillance. In practice, a DPIA for pharma AI is often a combined GDP risk assessment and DPIA.

For clinical research, EU CTR 536/2014 and ICH GCP E6(R3) apply; for medical devices, MDR 2017/745 and IVDR 2017/746. For cybersecurity in healthcare IT chains, this connects to our work on NEN 7510-compliant software. For structural AI implementation, it links to our AI development practice.

It starts with an intake, usually with the QA lead, an operations or supply representative, an IT or CSV representative and, depending on your organisation, an RP, QP or CTSU manager. We discuss the target audience, existing AI activities, the validated landscape, IoT suppliers, the serialisation platform and the eQMS stack. Based on that, we propose a programme, which we send to you in advance.

The workshop then takes place. We work in clear blocks: a short introduction to the subject, a longer hands-on or analysis exercise, and at the end a starting point for a follow-up roadmap. For the hands-on blocks, we ask in advance which documents you would like to use, such as anonymised deviation reports, fictitious CAPA wording, examples of temperature reports or customer emails from complaint handling, and we build the exercises around them. Afterwards you receive a written wrap-up: which modules were covered, who attended, which priorities were discussed and which next steps we agreed. This material can serve as documentation for Article 4 of the AI Act and as an annex to a GDP audit trail around the introduction of AI.

The workshop is not an end goal but a starting point. For some pharma organisations, one session is enough: a shared picture and a set of follow-up questions for the management team. For others, it becomes the trigger to go further: a pilot on anomaly detection in the cold chain, a batch recall impact tool, or the development of new healthcare or pharma software in which an AI component is delivered from day one within the boundaries of Annex 11 and NEN 7510. Both outcomes are legitimate.